reSET-O治疗阿片类药物使用障碍后医疗资源利用的实际减少
评估reSET-O数字治疗对阿片类药物使用障碍患者医疗资源利用影响的回顾性索赔研究数据集。

基本信息
资源简介
reSET-O治疗阿片类药物使用障碍后医疗资源利用的实际减少
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集,收录 1 个文件、合计 17.73 KB,主题涵盖 Opioid use disorder (OUD)、prescription digital therapeutic (PDT)、reSET-O、therapeutic education system (TES)、community reinforcement approach (CRA),可用于统计建模、特征工程与队列分析,CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic》。配套论文《Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic》发表于 Expert Review of Pharmacoeconomics & Outcomes Research(2020),DOI:10.1080/14737167.2021.1840357。项目资助方:This work was supported by Pear Therapeutics, Inc.。源站首次发布:2020-11-04。
【数据内容】
源站原始描述:Buprenorphine medication assisted treatment (B-MAT) adherence for opioid use disorder (OUD) is suboptimal. reSET-O, an FDA-cleared prescription digital therapeutic, delivers neurobehavioral therapy (community-reinforcement approach+fluency training+contingency management) to B-MAT-treated OUD patients. This retrospective claims study (10/01/2018-10/31/2019) evaluated healthcare resource utilization up to 6 months before/after reSET-O initiation. Repeated-measures negative binomial models compare…
【数据结构与技术规格】
文件数 1 个,合计 17.73 KB。ierp_a_1840357_sm2216.xlsx:application/vnd.openxmlformats-officedocument.spreadsheetml.sheet,17.73 KB。数据集 DOI:10.6084/m9.figshare.13187512.v1。
【主题与分类】
源站学科分类:Medicine、Pharmacology、Biotechnology、Ecology、Mental Health。主题标签:Opioid use disorder (OUD)、prescription digital therapeutic (PDT)、reSET-O、therapeutic education system (TES)、community reinforcement approach (CRA)、contingency management (CM)。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面:https://tandf.figshare.com/articles/dataset/Real-world_reduction_in_healthcare_resource_utilization_following_treatment_of_opioid_use_disorder_with_reSET-O_a_novel_prescription_digital_therapeutic/13187512
使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。
规范引用:Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic. Taylor & Francis. Velez, Fulton F.; Colman, Sam; Kauffman, Laura; Ruetsch, Charles; Anastassopoulos, Kathryn
【使用注意】
· 源站最后修改于 2023-05-31,引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取(Figshare)
- 源站标题:Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic
- DOI:10.6084/m9.figshare.13187512.v1
- 发布日期:2020-11-04
- 文件数:1 个
- 文件总体积:17.73 KB
- 源站页面:https://tandf.figshare.com/articles/dataset/Real-world_reduction_in_healthcare_resource_utilization_following_treatment_of_opioid_use_disorder_with_reSET-O_a_novel_prescription_digital_therapeutic/13187512
命令行下载
curl -L -o "ierp_a_1840357_sm2216.xlsx" "https://ndownloader.figshare.com/files/25387819"
文件清单
ierp_a_1840357_sm2216.xlsx(17.73 KB)
文件总体积 17.73 KB(源站 API 实测)。
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
Buprenorphine medication assisted treatment (B-MAT) adherence for opioid use disorder (OUD) is suboptimal. reSET-O, an FDA-cleared prescription digital therapeutic, delivers neurobehavioral therapy (community-reinforcement approach+fluency training+contingency management) to B-MAT-treated OUD patients.
This retrospective claims study (10/01/2018-10/31/2019) evaluated healthcare resource utilization up to 6 months before/after reSET-O initiation. Repeated-measures negative binomial models compared incidences of encounters/procedures. Net change in costs was assessed.
Among 351 patients (mean age 37; 59.5% female; 82.6% Medicaid), 334 had pharmacy claims and 240 (71.9%) received buprenorphine pre-/post-index (medication possession ratio 0.73 and 0.82, respectively; P = 0.004). Facility encounters decreased, with 45 fewer inpatient (P = 0.024) and 27 fewer emergency department (ED) visits (P = 0.247). Clinical encounters with largest changes were drug testing (638 fewer; P 0.001), psychiatry (349 fewer; P = 0.036), case management (176 additional; P = 0.588), other pathology/laboratory (166 fewer; P = 0.039), office/other outpatient (154 fewer; P = 0.302), behavioral rehabilitation (111 additional; P = 0.124), alcohol/substance rehabilitation (96 fewer; P = 0.348), other rehabilitation (66 fewer; P = 0.387), mental health rehabilitation (61 additional; P = 0.097), and surgery (60 fewer; P = 0.070). Changes in facility/clinical encounters saved $2,150/patient.
reSET-O initiation was associated with fewer inpatient, ED, and other clinical encounters, increased case management/rehabilitative services, and lower net costs over six months.
Real-world evidence is helpful in evaluating the effectiveness of interventions in usual-care conditions, outside of controlled research environments. Large observational studies based on health care claims are important to understand the actual pharmacoeconomic and outcomes impact of interventions at the health care system and population level.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.13187512.v1(source: https://tandf.figshare.com/articles/dataset/Real-world_reduction_in_healthcare_resource_utilization_following_treatment_of_opioid_use_disorder_with_reSET-O_a_novel_prescription_digital_therapeutic/13187512)。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




